New drug duo tested for Tough-to-Treat bile duct cancer
NCT ID NCT04781192
Summary
This study is testing whether combining two drugs, regorafenib and durvalumab, can help control advanced bile duct cancer that has continued to grow after standard chemotherapy. It is for up to 40 patients whose cancer has worsened despite one prior treatment. The main goals are to see how safe the combination is and if it can slow the cancer's progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Kansas Medical Center
North Kansas City, Missouri, 64116, United States
-
The University of Kansas Medical Center
Westwood, Kansas, 66205, United States
-
University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri, 64064, United States
-
University of Kansas Cancer Center - North
Kansas City, Missouri, 64154, United States
-
University of Kansas Cancer Center - Overland Park
Overland Park, Kansas, 66210, United States
Conditions
Explore the condition pages connected to this study.